May 6, 2020
IVERIC bio Reports First Quarter 2020 Operational Highlights and Financial Results
– Conference Call and Webcast Today, May 6, 2020, at 8:00 a.m. ET – NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq:…
Pharmaceuticals, Biotechnology and Life Sciences
– Conference Call and Webcast Today, May 6, 2020, at 8:00 a.m. ET – NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq:…
– Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for…
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3…
Company expands expertise in TBI pathology, biomarkers and clinical development as PNT001 advances through the clinic CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pinteon Therapeutics,…
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended…
U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental New Drug Application (sNDA) for RECARBRIO in Hospital-Acquired or…
1Q20 total revenues of $1,444.8 million, a 27 percent increase over 1Q19 1Q20 GAAP diluted EPS of $2.50; non-GAAP diluted…
Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19 MONTREAL–(BUSINESS WIRE)–Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company,…
— First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3 — UTRECHT, The Netherlands–(BUSINESS…